[Email to David Baltimore from Bruce Weniger with Draft of PACHA Recommendations]

Rockefeller Foundation)

41. Norman L. Letvin, MD
Chief, Division of Viral Pathogenesis, Beth
Israel Hospital
Professor of Medicine, Harvard Medical School
42. John Moore, PhD
Staff Investigator
Aaron Diamond AIDS Research Center
43. Lendon Payne, MD, PhD
Director of Research,
Virus Research Institute, Inc.
44. Kathleen Scutchfield
Co-founder
Until There's a Cure Foundation
45. Robert T. Schooley, MD
Professor of AIDS Research
University of Colorado Health Sciences Center
46. Jonathan T. Warren, PhD
Immunologist, AIDS Vaccine Evaluation Group
The EMMES Corporation
47. Peter F. Wright, MD
Director, AIDS Vaccine Evaluation Unit
Professor of Pediatrics, Vanderbilt University
School of Medicine
APPENDIX C: REFERENCE DOCUMENTATION
AIDS Vaccine Advocacy Coalition (AVAC). Industry
investment in HIV vaccine research. December, 1996.
(www.vactup.org/avac/contents.html).
AIDS Vaccine Development Policy & Issues.
(hsph. harvard.edu/organizations/hailvaccines/preamble. html)
Avrett, S. (1997). AIDS vaccine. Healthlink,
Aug/Sept, 6-7.
Cohen, Jon. (1995). Thailand weighs AIDS vaccine
tests. Science, 270, 904-907.
Collins, Chris. (1997). Industry investment in HIV vaccine
research. SIDAlerte Quarterly TB & HIV, 14, May, 13, 19, 20.
Harvard AIDS Institute. HIV vaccines for developing
countries: designing efficacy trials. 07/28/97.
(www. hsph. harvard.edu/organi...cines/design ing
efficacytrials.html).
Esparza, J., Heyward, W. L., & Osmanov, S. (1996).
HIV Vaccine Development: From basic research to
human trials. AIDS, 10 (suppl A), s123-sl32.
Fast, P. E., Mathieson, B. J., Schultz, A.M. (1994).
Efficacy trials of AIDS vaccines: How science can
inform ethics. Current Opinion in Immunology, 6,
691-697.

Francis, D. P., & Kennedy, D. (1994). A private-sector
AIDS vaccine? Don't hold your breath. (Op-ed),
The Washington Post, (July 19).
Frnnc.i. fl P (199'1 Why AIIR vaccin, d.vainnm.nt